Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer / M.L. Gillison, G. Blumenschein, J. Fayette, J. Guigay, A.D. Colevas, L. Licitra, K.J. Harrington, S. Kasper, E.E. Vokes, C. Even, F. Worden, N.F. Saba, L.C. Iglesias Docampo, R. Haddad, T. Rordorf, N. Kiyota, M. Tahara, M. Monga, M. Lynch, L. Li, R.L. Ferris. - In: THE ONCOLOGIST. - ISSN 1083-7159. - 23:9(2018 Sep), pp. 1079-1082.
|Titolo:||CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||set-2018|
|Data ahead of print / Data di stampa:||4-giu-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1634/theoncologist.2017-0674|
|Appare nelle tipologie:||01 - Articolo su periodico|